文献速递白血病造血干细胞移植与细胞治疗

北美母细胞性浆细胞样树突状细胞肿瘤联盟:诊疗标准立场与需求领域

North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
PubMed 文献 · Blood · 2023-01-01

母细胞性浆细胞样树突状细胞肿瘤(BPDCN)罕见、预后差且无全球共识方案;北美BPDCN联盟(NABC)由血液肿瘤、移植、病理、皮肤及儿科肿瘤专家组成,明确当前诊疗标准并列出关键研究问题与未来方向。

要点

  • BPDCN常累及皮肤,也可侵犯中枢神经系统等髓外部位,多见于老年人。
  • 所有BPDCN均表达CD123(IL3Rα),为可靶向的表面标志物。
  • 靶向CD123的tagraxofusp于2018年12月在美国获批用于≥2岁BPDCN患者。

核心结论

  • NABC首次会议形成BPDCN当前诊疗标准立场,并确定最重要研究问题与未来方向。

研究设计与样本

  • NABC为多学科专家协作组,成员包括血液肿瘤科、造血干细胞移植科、病理科、皮肤科及儿科肿瘤科医生。

主要发现

  • BPDCN为罕见血液恶性肿瘤,历史预后差,无全球共识治疗方案。
  • BPDCN常累及皮肤,也可侵犯中枢神经系统等髓外部位;多见于老年人,许多患者不适合强化化疗。
  • 年轻适合者可考虑造血干细胞移植,但并非所有患者均符合条件。
  • 所有BPDCN均表达CD123(IL3Rα),该表面标志物可被药物靶向。
  • 靶向CD123的tagraxofusp于2018年12月在美国获批用于≥2岁BPDCN患者。

关键数值与推荐

  • tagraxofusp为BPDCN首创药物,靶向CD123,2018年12月在美国获批用于≥2岁BPDCN患者。
  • 一线单药治疗虽缓解率良好,但许多患者仍复发,复发/难治BPDCN结局仍差。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare hematologic malignancy with historically poor outcomes and no worldwide consensus treatment approach. Unique among most hematologic malignancies for its frequent cutaneous involvement, BPDCN can also invade other extramedullary compartments, including the central nervous system. Generally affecting older adults, many patients are unfit to receive intensive chemotherapy, and although hematopoietic stem cell transplantation is preferred for younger, fit individuals, not all are eligible. One recent therapeutic breakthrough is that all BPDCNs express CD123 (IL3Rα) and that this accessible surface marker can be pharmacologically targeted. The first-in-class agent for BPDCN, tagraxofusp, which targets CD123, was approved in December 2018 in the United States for patients with BPDCN aged ≥2 years. Despite favorable response rates in the frontline setting, many patients still relapse in the setting of monotherapy, and outcomes in patients with relapsed/refractory BPDCN remain dismal. Therefore, novel approaches targeting both CD123 and other targets are actively being investigated. To begin to formally address the state of the field, we formed a new collaborative initiative, the North American BPDCN Consortium (NABC). This group of experts, which includes a multidisciplinary panel of hematologists/oncologists, hematopoietic stem cell transplant physicians, pathologists, dermatologists, and pediatric oncologists, was tasked with defining the current standard of care in the field and identifying the most important research questions and future directions in BPDCN. The position findings of the NABC's inaugural meetings are presented herein.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pemmaraju N, Kantarjian H, Sweet K, et al. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need. Blood. 2023. PMID: 36399715. doi:10.1182/blood.2022017865

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。